ETC-1002 Lowers LDL-Cholesterol and is Well Tolerated in Hypercholesterolemic Patients with Statin Intolerance†

Methods: 56 patients with a history of statin intolerance involving muscle pain or weakness stopped lipid-lowering agents and received single-blinded PBO for 2 weeks. Patients were excluded if musclerelated AEs were reported during the single-blinded period. Remaining patients were randomized to receive PBO (n=19) or ETC-1002 in daily doses increasing from 60 to 120 to 180 to 240 mg (n=37) every two weeks over 8 weeks of treatment. The primary endpoint was percent change in LDL-C from baseline to Week 8.